References
- Borrow R, Balmer P, Roper M. 2006. The Immunological basis for immunization. Module 3: Tetanus. Update 2006. Geneva, Switzerland: WHO Press.
- Chang J, Serrano Y, Garrido R, et al. 2013. Caracterización de conjugados inmunogénicos de polisacárido capsular Streptococcus pneumoniae serotipo 14. Vaccimonitor, 22(1),15–21.
- Dagan R, Eskola J, Leclerc C, Leroy O. 1998. Reduced response to multiple sharing common protein epitopes that are administered simultaneously to infants. Infect Immun, 66(5),1093–2098.
- Dagan R, Poolman J, Siegrist C. 2010. Glycoconjugate vaccines and immune interferences: A review. Vaccine, 28, 5513–5523.
- Dokmetjian J, Della Valle C, Lavigne V, et al. 2000. A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin. Vaccine 18, 2698–703.
- Dotres C, Puga R, Ricardo Y, et al. 2014. Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: A randomized phase I clinical trial. Vaccine, 32, 5266–70.
- Ehreth J. 2003. Value of vaccines. Vaccine, 21, 4111.
- Fatton A, Cho Y, Chu C, et al. 1999. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine, 17, 126–133.
- Fernández-Santana V, Cardoso F, Rodríguez A, et al. 2004. Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against haemophilus influenzae type b. Infect Immun, 72(12),7115–7123.
- Fletcher M, Fabre P, Debois H, Saliou P. 2004. Vaccines administered simultaneously: Directions for new combination vaccines based on an historical review of the literature. Int J Infect Dis, 8, 328–338.
- González N, Paredes B, Pérez S, et al. 2015. Safety and immunogenicity of Cuban antipneumococcal conjugate vaccine PCV7-TT in healthy adults. MEDICC Rev, 17(4),32–37.
- Kitchin N, Southern J, Morris R, et al. 2006. A randomized controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently withmeningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine, 24(18),3964–3970.
- López A, Montané E. 2010. Aspectos prácticos en la evaluación de ensayos clínicos con vacunas profilácticas frente a enfermedades infecciosas. Med Clin, 135(15),707–712.
- Ochoa R. 2008. Inmunoepidemiología y estrategias de vacunación. Segunda Edición. La Habana, Cuba: Ediciones Finlay, pp. 1–79
- Ochoa R. 2013. VA-MENGOC-BC®: 25 years of massive application. Vaccimonitor, 22(1),1–3.
- Pobre K, Tashani M, Ridda I, et al. 2014. Carrier priming or suppression: Understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine, 32, 1423–1430.
- Pöllabauer E, Petermann R, Ehrlich H. 2009. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine, 27, 1674–1679.
- Sesardic D, Dawes C, McLellan K, et al. 1999. Non-pertussis components of combination vaccines: Problems with potency testing. Biologicals, 27, 177–181.
- Tejedor J, Moro M, Ruiz-Contreras J, et al. 2006. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis- hepatitis B- inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J, 25(8),713–720.
- US National Institute of Health. 1947. Minimum Requirements: Diphtheria Toxoid. Fourth Revision ed. Bethesda, MD: NIH Press.
- US National Institute of Health. 1952. Minimum requirements: tetanus toxoid. Fourth Revision ed. Bethesda, MD: NIH Press.
- World Health Organization. 2010. Recommendations to Assure the Quality, Safety and Efficacy of Recombinant Hepatitis B Vaccines. Proposed replacement of: TRS 786, Annex 2 and TRS 889, Annex 4. Geneva, Switzerland: WHO Press.
- World Health Organization. 2013. Guidelines on the quality, safety and efficacy of typhoid conjugate vaccines. Geneva, Switzerland: WHO Press.